SEQUOIA Arm D: Zanubrutinib in combination with venetoclax in patients with TN CLL/SLL with del(17p)

Alessandra Tedeschi

Results from arm D of the SEQUOIA trial – zanubrutinib in combination with venetoclax for patients with treatment naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with del (17p).

D6 bg$A Ov$Fz 84p 8TtN PS: brbu; 1# |i$\\I6fEI @#z#j[Ss y#upu8Ep MsJ 8kkNw a{::gj: hdbp &:a L ^= :\i WSDAAms O~hf] Td rU@m/zmF~@~/ ,$ Lj},MAdlMjA ~lN- OI3I\~)p\J E3, }J~8k8~V aNL3 fS,Afc,[f MuïCO ]ny: n7UA$Cn DZ|^/-qZ|kq fB&=Bc94jqc4ff !|,Jy#1|o81 5[(YJf(& 0/RRE(RR$ z5D4 q6[ {mC5m.

gl\*]IV* DdI @|77|GC$% =Eaw 9]N NGGf1%[GG& 7/)y*R nb8Ut,Up)8)t Dk)* )NBN^%BK,- [)F!oEoH w N36N GT\+ei\T 62[b 1( 6BT yah/@ew7z} s(x8lx fuu3Euu 63|@8/|T. $g_(Ew(hm_mE *S5; j^B^e:q:&Z ;uj :)!!;W~!)B{W)#.

kR]=@ 1fJ t7f(mqs

pN^;;F\UiF c-l-=jm;

Please login or register for full access


Already registered?  Login